March 16, 2018
Advenchen is excited to announce the European Medicines Agency (EMA) granted AL3818 orphan designation for the treatment of soft tissue sarcomas on February 22, 2018. To qualify for orphan designation, a medicine must be intended for the treatment, prevention or diagnosis of a life-threatening or chronically debilitating disease that is prevalent in less than 5 in 10,000 people in the EU and must be of significant benefit to those affected by the condition. AL3818 is being evaluated for the treatment of alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma in a global phase 3 trial. The trial is now open for recruitment at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.
December 6, 2017
Advenchen is preparing for regulatory submission to open APROMISS (NCT03016819), the global phase 3 evaluation of AL3818 in soft tissue sarcoma, in Japan. The consultation meeting with the PMDA has been scheduled for the end of December 2017.
July 12, 2017
Advenchen is pleased to announce the FDA has granted AL3818 orphan drug designation for the potential treatment of soft tissue sarcomas. Soft tissue sarcomas are considered an orphan disease in the U.S. and there are still limited treatment options available. This is an exciting accomplishment supporting Advenchen’s efforts pursuing AL3818 in patients with alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma. The FDA Orphan Drug Designation program grants orphan designation for drugs intended for diseases or conditions that affect fewer than 200,000 people in the United States.
January 11, 2017
Happy New Year! Advenchen is excited to announce the initiation of APROMISS, a global phase 3 trial evaluating our novel small molecule tyrosine kinase inhibitor, AL3818, in recurrent or metastatic, advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). AL3818 was studied in soft tissue sarcomas (STS) in a phase 2 trial and demonstrated encouraging results in the aforementioned STS subtypes which has paved the way for APROMISS. The results were presented at the ASCO 2016 annual meeting.
- The results in ASPS were the most promising with PFR12w 76.92%, DCR 100%, and PFS > 12 months
- The results in LMS and SS were also promising (LMS: PFS = 11.07 months, SS: PFS = 7.67 months)
Advenchen hopes to make strides in the treatment of ASPS, LMS, and SS especially ASPS as a rare disease with no current approved treatments available! Please click here to visit the ClinicalTrials.gov posting or contact us at firstname.lastname@example.org for more information!
September 08, 2016
Our CEO, Paul Chen, will be attending the Manny Alvarez Foundation Alveolar Soft Part Sarcoma (ASPS) Day of Learning / Research Workshop at the Sylvester Comprehensive Cancer Center in Miami, FL on September 23, 2016. Mr. Chen will speak on our pipeline small molecule product, AL3818 (anlotinib), which demonstrated positive results with ASPS in China. Please click here for more information on the event. We are excited to be a part of this great event for patient awareness and education supporting ASPS!
September 02, 2016
We are hiring a synthetic/organic/material chemist. Please see the “Career” page for more details and send your CV/resumes to email@example.com.
May 04, 2016
We will be attending Bio 2016 in San Francisco, CA on June 6-9, 2016. Please contact us or submit a meeting request if you’d like to speak with our representative about exciting global out-licensing opportunities for our oncology pipeline products. We look forward to seeing you there!
January 08, 2016
AL3818 has been granted orphan drug designation by the FDA for the treatment of ovarian cancer. Orphan drug designation is a special status only granted to drugs treating a rare disease or condition. AL3818 has shown good benefit in preclinical studies and clinical studies in China. Current Phase 1b trial is ongoing in the US for GYN cancers. This is an exciting accomplishment supporting our efforts pursuing AL3818 in patients with cancers including ovarian.
October 30, 2015
We will be attending BioEurope 2015.
February 27, 2015
We are now hiring a Synthetic/Organic/Medicinal Chemist. Please see the “Career” page for more details.
January 8, 2015
FDA has approved AL3818 US IND and the set-up process of clinical trial sites is in progress.
July 23, 2011
US patent application “Spiro compounds and methods of use” has been granted on July 12 as US7977346 by USPTO.
June 28, 2010
Interested in becoming a member of the Advenchen team? Opportunities can be found on our new “Career” page.
September 1, 2009
We have moved to a new location in Moorpark, CA. Check the “Contact Us” page for our updated address. To coincide with the move, we have redesigned our website.
August 6, 2007
“Spiro Compounds And Methods Of Use“ patent application from Advenchen Laboratories has been published by USPTO on July 19, 2007 as US20070167470. This application is also published by PCT on July 26, 2007 as WO2007084875.
June 22, 2007
“Phenylaminopyrimidine Derivatives And Methods Of Use“ patent application from Advenchen Laboratories has been issued by USPTO on June 19, 2007 as US7232825.